Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antagonism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Antagonism. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-000944-98 Sponsor Protocol Number: UNC4024 Start Date*: 2005-05-02
    Sponsor Name:Norlands University Hospital
    Full Title: FARMAKOKINETISKA EGENSKAPER HOS ISOALLOPREGNANOLON OCH ANTAGONISM AV ALLOPREGNANOLONS SEDERINGS EFFEKT HOS KVINNOR. Pharmacokinetic properties of isoallopregnanolone and antagonism of allopregnano...
    Medical condition: Premenstrual Dysphoric Disorder (PMDD) / Severe Premenstrual Syndrome (PMS)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007604-15 Sponsor Protocol Number: STH14971 Start Date*: 2009-03-03
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome
    Medical condition: Sub Clinical Cushing's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002313-18 Sponsor Protocol Number: PAMORA-AP_2020 Start Date*: 2020-12-22
    Sponsor Name:Mech-Sense, Aalborg University Hospital
    Full Title: The effects of opioid receptor antagonism on acute pancreatitis: An investigator initiated, randomized, placebo-controlled, double-blind clinical trial
    Medical condition: Acute pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10033647 Pancreatitis acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017193-20 Sponsor Protocol Number: S51994 Start Date*: 2010-01-28
    Sponsor Name:UZLeuven
    Full Title: Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers.
    Medical condition: healthy volunteers none; this is a physiological study to investigate the influence of opioid antagonism on gastric sensorimotor function
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006082-88 Sponsor Protocol Number: Rimonamaag Start Date*: 2008-10-21
    Sponsor Name:UZLeuven
    Full Title: INFLUENCE OF RIMONABANT ON GASTRIC SENSITIVITY AND ON THE GASTRIC RESPONSE TO A MEAL IN HEALTHY VOLUNTEERS
    Medical condition: none; this is a physiological study to investigate the influence of CB1 receptor antagonism by rimonabant (normally used for the treatment of obesity) on gastric sensorimotor function
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000986-40 Sponsor Protocol Number: EVT 101/1002 Start Date*: 2007-08-07
    Sponsor Name:Evotec NeurosciencesGmbH
    Full Title: A double blind, placebo controlled study to investigate the role of NMDA receptor NR2B subunit selective antagonism on cognitive functions and neurophysiology in healthy subjects as measured with MRI
    Medical condition: Investigation of cognitive function and neurophysiology.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004399-35 Sponsor Protocol Number: Pfi-RW-2005-01 Start Date*: 2005-01-18
    Sponsor Name:North Glasgow Trust
    Full Title: The effects of eplerenone on left ventricular remodelling post-acute myocardial infarction: a double-blind placebo-controlled cardiac MR-based study.
    Medical condition: Post-myocardial infarction left ventricular dysfunction, in the absence of heart failure - clinical (i.e. Killip III or IV) or radiological - nor established diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005513-40 Sponsor Protocol Number: 2012-005513-40 Start Date*: 2013-05-28
    Sponsor Name:HYKS Psykiatrikeskus
    Full Title: Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004687-37 Sponsor Protocol Number: 14SM2335 Start Date*: 2016-06-17
    Sponsor Name:Imperial College Healthcare NHS Trust
    Full Title: Use of Methylnaltrexone for the Treatment of Opioid Induced Constipation & Gastro-Intestinal Stasis in Intensive Care Patients
    Medical condition: Opioid Induced Constipation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002672-13 Sponsor Protocol Number: RH/BARACKD/0003 Start Date*: 2013-04-09
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance Office
    Full Title: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial: a prospective randomised open blinded endpoint trial to determine the effect of aldosterone receptor antagoni...
    Medical condition: We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate marke...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    15.1 10022891 - Investigations 10018355 Glomerular filtration rate PT
    15.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001496-21 Sponsor Protocol Number: LOC-2013 Start Date*: 2013-06-18
    Sponsor Name:Harry Scheinin
    Full Title: The Neural Mechanisms of Anesthesia and Human Consciousness
    Medical condition: No medical condition or disease involved. The study subjects are healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004982-10 Sponsor Protocol Number: LOC-2016 Start Date*: 2015-12-15
    Sponsor Name:Harry Scheinin
    Full Title: The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)
    Medical condition: No medical condition or disease involved. The study subjects are healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002976-14 Sponsor Protocol Number: CRI103143 Start Date*: 2006-09-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of ...
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002623-42 Sponsor Protocol Number: 66623 Start Date*: 2019-02-18
    Sponsor Name:Academic Medical Center
    Full Title: Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study
    Medical condition: Vasospastic angina, i.e. epicardial vasospasm or microvascular coronary dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001567-55 Sponsor Protocol Number: DAC-1012 Start Date*: 2006-06-23
    Sponsor Name:Protein Design Labs, Inc.
    Full Title: A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis
    Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004912-30 Sponsor Protocol Number: aprepitant1 Start Date*: 2008-07-31
    Sponsor Name:Karolinska Institutet
    Full Title: Modulation of opiate reward by NK1 antagonism: A laboratory based proof of concept study
    Medical condition: opiate abuse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039004 Reversal of opiate activity LLT
    9.1 10012346 Dependence on opiates LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023366-49 Sponsor Protocol Number: Bosentan for HPS Start Date*: 2011-07-22
    Sponsor Name:Med. Univ. Wien, Univ. Klinikum für Interne Medizin III
    Full Title: Bosentan for treatment ofhepatopulmonary syndrome in patients with liver cirrhosis - a prospective double blind randomized controlled clinical study
    Medical condition: HPS is by far the most frequent respiratory complication of cirrhosis leading to significantly increased mortality. The only therapeutic option is liver transplantation. Many patients with HPS who ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006081-29 Sponsor Protocol Number: Rimonaslok Start Date*: 2008-10-21
    Sponsor Name:UZLeuven
    Full Title: INFLUENCE OF RIMONABANT ON LOWER ESOPHAGEAL FUNCTION IN HEALTHY VOLUNTEERS
    Medical condition: none; this is a physiological study to investigate the influence of CB1 receptor antagonism by rimonabant (normally used for the treatment of obesity) on esophageal function, i.e. esophageal contr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017924 Gastroesophageal reflux LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008713-20 Sponsor Protocol Number: BGC20-1531-04 Start Date*: 2009-03-26
    Sponsor Name:Danish Headache Center
    Full Title: EP4 receptor antagonism and PGE2 in a human headache model
    Medical condition: PGE2 will induce headache in healthy subjects and BGC20-1531 or placebo will be used to block the developement of headache. In the future BGC20-1531 might be a possible anti-migraine drug.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001360-20 Sponsor Protocol Number: MINECRAFT Start Date*: 2021-07-29
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: MINECRAFT Study: MINEralcorticoid receptor antagonism with CanRenone As eFfective Treatment in moderate to severe ARDS in COVID-19, a phase 2 clinical trial.
    Medical condition: SARS-CoV2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:11:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA